Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Potential Side Effects AOD-9604 is generally well-tolerated
But the evidence is quite sparce
10.1136/bmj.301.6756.853 84 MalkovM
In the pooled Phase 3 RECONNECT program (two identically designed double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD), bremelanotide 1.75 mg administered subcutaneously on demand produced statistically significant improvements over placebo on both co-primary endpoints the Female Sexual Function Index Desire Domain and the Female Sexual Distress Scale (Desire/Arousal/Orgasm) Question 13 with P 99% (HPLC, LCMS) Container: Sealed metered nasal spray bottle Documentation: Batch-specific Certificate of Analysis (COA) available Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page
Observe for rare allergic reactions and ensure follow-up labs
